Literature DB >> 29538038

Recurrence rate and overall survival of operated ruptured hepatocellular carcinomas.

Gaëtan-Romain Joliat1, Ismail Labgaa, Emilie Uldry, Nicolas Demartines, Nermin Halkic.   

Abstract

OBJECTIVE: Hepatocellular carcinomas (HCC) can infrequently rupture and cause hemorrhage. Little is known on recurrence rate (RR) and overall survival (OS) in case of ruptured HCC. This study aimed to assess RR, time to recurrence, and OS of operated ruptured HCC. PATIENTS AND METHODS: All operated patients with HCC (1999-2015) were reviewed. Patient demographics, perioperative details, and postoperative outcomes of ruptured HCC were recorded. RR, time to recurrence, and OS were calculated. RR and OS of ruptured and non-ruptured HCC were compared.
RESULTS: Among the 140 consecutive patients with HCC operated during the study period, 14 presented with rupture. Eleven patients had cirrhosis (all Child-Pugh A). At presentation, median α-fetoprotein and hemoglobin levels were 23 µg/l (interquartile range: 5-883) and 127 g/l (118-148), respectively. All but one patient felt abdominal pain, and two were in hemorrhagic shock. Preoperative embolization with staged hepatectomy was performed in seven patients. Five patients were first treated conservatively and then had an elective hepatectomy, whereas two patients had upfront surgery (one packing and one segmentectomy). Major hepatectomy was performed in eight cases. Median intraoperative blood loss was 1000 ml (500-2100). Overall complication rate was 36%. Eight patients presented a recurrence (57%; median time to recurrence: 8 months; interquartile range: 6-19). Median OS was 44 months, and 5-year OS was 41%. The 126 operated patients with non-ruptured HCC had a RR of 59/126 (47%; P=0.576) and a 5-year OS of 61% (P=0.448).
CONCLUSION: RR between ruptured and non-ruptured HCC were similar. Moreover, HCC rupture did not impair OS compared with HCC without rupture.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29538038     DOI: 10.1097/MEG.0000000000001115

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  7 in total

1.  Spontaneous Rupture of Hepatocellular Carcinoma: New Insights.

Authors:  Adham E Obeidat; Linda L Wong
Journal:  J Clin Exp Hepatol       Date:  2021-05-29

2.  Early experience with laparoscopic liver resection for spontaneously ruptured hepatocellular carcinoma.

Authors:  Tousif Kabir; Zoe Z X Tan; Darren Weiquan Chua; Nicholas Syn; Brian K P Goh
Journal:  J Minim Access Surg       Date:  2020 Jul-Sep       Impact factor: 1.407

Review 3.  Ruptured Hepatocellular Carcinoma: Current Status of Research.

Authors:  Feng Xia; Elijah Ndhlovu; Mingyu Zhang; Xiaoping Chen; Bixiang Zhang; Peng Zhu
Journal:  Front Oncol       Date:  2022-02-17       Impact factor: 6.244

4.  Effect of Perioperative Blood Transfusion on the Postoperative Prognosis of Ruptured Hepatocellular Carcinoma Patients With Different BCLC Stages: A Propensity Score Matching Analysis.

Authors:  Feng Xia; Qiao Zhang; Zhiyuan Huang; Elijah Ndhlovu; Mingyu Zhang; Xiaoping Chen; Bixiang Zhang; Peng Zhu
Journal:  Front Surg       Date:  2022-03-22

5.  Prognostic Analysis of Postoperative Survival for Ruptured Hepatocellular Carcinoma with or without Cirrhosis.

Authors:  Feng Xia; Peng Zhu; Xiao-Ping Chen; Bi-Xiang Zhang; Ming-Yu Zhang
Journal:  J Oncol       Date:  2022-03-17       Impact factor: 4.375

6.  Alpha-Fetoprotein+Alkaline Phosphatase (A-A) Score Can Predict the Prognosis of Patients with Ruptured Hepatocellular Carcinoma Underwent Hepatectomy.

Authors:  Feng Xia; Elijah Ndhlovu; Zhicheng Liu; Xiaoping Chen; Bixiang Zhang; Peng Zhu
Journal:  Dis Markers       Date:  2022-04-21       Impact factor: 3.464

7.  The β-catenin/TCF-4-LINC01278-miR-1258-Smad2/3 axis promotes hepatocellular carcinoma metastasis.

Authors:  Wei-Juan Huang; Xiao-Peng Tian; Si-Xue Bi; Si-Rui Zhang; Ting-Sha He; Li-Yan Song; Jing-Ping Yun; Zhong-Guo Zhou; Rong-Min Yu; Mei Li
Journal:  Oncogene       Date:  2020-05-05       Impact factor: 9.867

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.